Chemed Corporation to Present at the Oppenheimer 34th Annual Healthcare Conference
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 34th Annual Healthcare Conference on Tuesday, March 12, 202...
Is Chemed (CHE) a Solid Growth Stock? 3 Reasons to Think "Yes"
Chemed (CHE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Chemed (CHE) Q4 Earnings Surpass Estimates, Margins Expand
Chemed's (CHE) fourth-quarter 2023 performance reflects an improvement in VITAS' operational metrics.
Chemed (CHE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Chemed (CHE) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street esti...
Chemed (CHE) Tops Q4 Earnings Estimates
Chemed (CHE) came out with quarterly earnings of $6.60 per share, beating the Zacks Consensus Estimate of $6.25 per share. This compares to earnings of $5.39 per share a year ago.
Chemed (CHE) Roto-Rooter Growth Continues, Macro Issues Hurt
Within the Hospice segment, Chemed (CHE) is well poised to register growth driven by the growing aging population.
Chemed Corporation to Present at the 42nd Annual JPMorgan Healthcare Conference
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the 42nd Annual JPMorgan Healthcare Conference on Monday, January 8, 2024, at appro...
Three-Stock Lunch: Cintas, Chemed and CrowdStrike
David Wagner, portfolio manager at Aptus Capital Advisors, joins 'Power Lunch' to discuss three stocks: Cintas, Chemed and CrowdStrike.
Chemed: Continues To Compound Shareholder Value At Double-Digit Returns
Chemed Corporation has historically matched long-term returns with minimal drawdown periods and durable economics. CHE has shown significant market growth over the years, compounding returns on sha...
Chemed's (CHE) VITAS Performance Aids, Macro Issues Linger
Chemed (CHE) believes Roto-Rooter is well-positioned for growth and anticipates continued expansion of the segment's market share.
Chemed (CHE) Q3 Earnings and Revenues Surpass, Margins Rise
Chemed's (CHE) third-quarter 2023 performance reflects strength in the VITAS segment.
Chemed Corporation (CHE) Q3 2023 Earnings Call Transcript
Chemed Corporation (NYSE:CHE ) Q3 2023 Earnings Conference Call October 26, 2023 10:00 AM ET Company Participants Holley Schmidt - Assistant Controller Kevin McNamara - President and Chief Executiv...
Chemed (CHE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Chemed (CHE) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street est...
Chemed (CHE) Q3 Earnings and Revenues Beat Estimates
Chemed (CHE) came out with quarterly earnings of $5.32 per share, beating the Zacks Consensus Estimate of $4.92 per share. This compares to earnings of $4.74 per share a year ago.
OPCH or CHE: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Option Care (OPCH) and Chemed (CHE). But which of these two stocks offers valu...
Related Companies